...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Upcoming CVOT results

I was taking a look at the advance program for American Diabetes Association (ADA) meeting in June 2019 and looks like a few diabetes CVOTs will be reporting full data.

 

GLP1-R agonists: REWIND (dulaglutide) will present full results at ADA 2019. Eli Lilly previously reported that dulaglutide significantly reduced 3-point MACE but did not report a %RRR. Perhaps the most anticipated results at ADA 2019 will be for the PIONEER program including the PIONEER 6 CVOT trial for oral semaglutide. This is the first orally available GLP1-R agonist; others are injectables. Like injectable semaglutide in SUSTAIN 6, oral semaglutide in PIONEER 6 was reported to reduce MACE.

 

SGLT2 inhibitors: CREDENCE (canagliflozin) will report full data at ADA 2019 for this renal/cardio trial. A prior renal/cardio trial for canagliflozin, CANVAS, reported 14% RRR for 3-point MACE. DECLARE-TIMI58 (dopagliflozin) previously reported a non-significant 7% RRR in 3-point MACE and non-significant 10% RRR for those with established cardiovascular disease, and this data will be presented at ADA 2019. An ongoing VERTIS-CV CVOT trial for ertugliflozin is estimated to be completed in H2 2019 and is not on schedule for ADA 2019.

 

DPP4 inhibitors: CARMELINA (Linagliptin) previously reported that it was neutral for 3-point MACE in a renal/cardio trial, but will be presenting full data at ADA 2019 along with another recently completed linagliptin CVOT trial called CAROLINA. In general, DPP4 inhibitors have not shown MACE reduction.

 

Omega-3s: These two trials are not being presented at ADA 2019, but are projected to complete H2 2019 or H1 2020: EVAPORATE plaque progression trial with Amarin’s Vascepa and STRENGTH CVOT trial with Astrazeneca’s EPANOVA.

Share
New Message
Please login to post a reply